Table 5. Factors associated with the development of hepatocellular carcinoma (HCC) in over 2-year or 3-year follow up model.
| Category | Cut off | Univariate | Multivariate (after 2 years, n = 1031) | Multivariate (after 3 years, n = 814) | ||||
|---|---|---|---|---|---|---|---|---|
| P value | P value | Hazard Ratio | 95%CI | P value | Hazard Ratio | 95%CI | ||
| Age | ≥73 years | 0.001 | ||||||
| Sex | Male | <0.001 | 0.017 | 2.326 | 1.163–4.652 | |||
| Etiology | Cirrhosis present | <0.001 | 0.003 | 5.775 | 1.792–18.613 | |||
| Prior DAA therapy | DAA experience | 0.574 | ||||||
| Platelet counts | <11.3×104 /μL | <0.001 | ||||||
| Total bilirubin | ≥0.8 mg/dL | 0.006 | ||||||
| AST | ≥47 U/L | <0.001 | ||||||
| ALT | ≥36 U/L | 0.078 | ||||||
| GGT | ≥31 U/L | 0.006 | ||||||
| Alb | <3.9 g/dL | <0.001 | ||||||
| Hyaluronic acid | ≥75 ng/mL | <0.001 | 0.011 | 4.085 | 1.389–12.015 | |||
| Fib-4 index | ≥4.03 | <0.001 | ||||||
| AFP | ≥7.1 ng/mL | <0.001 | ||||||
| EOT-ALT | Not WNL | 0.070 | ||||||
| EOT-Alb | <3.9 g/dL | <0.001 | 0.019 | 2.352 | 1.151–4.807 | |||
| EOT-AFP | ≥5.3 ng/mL | <0.001 | <0.001 | 4.272 | 2.061–8.858 | 0.002 | 6.237 | 1.933–20.123 |
95%CI, 95% confidence interval; DAA, direct-acting antivirals; AST, aspartate transaminase; ALT, alanine transaminase; GGT, γ-glutamyltransferase; Alb, albumin; AFP, α-fetoprotein; EOT, end of treatment; WNL, within normal limit.